Bervastatin, with the CAS number 132017-01-7, is a synthetic compound belonging to the class of statins, which are primarily used to lower cholesterol levels in the blood. Statins function by inhibiting the enzyme HMG-CoA reductase, a key player in the cholesterol biosynthesis pathway. Bervastatin is characterized by its ability to reduce low-density lipoprotein (LDL) cholesterol and triglycerides while potentially increasing high-density lipoprotein (HDL) cholesterol. This compound exhibits a favorable pharmacokinetic profile, including good oral bioavailability and a relatively long half-life, allowing for once-daily dosing. Additionally, bervastatin may possess anti-inflammatory properties and has been studied for its potential benefits beyond lipid-lowering, such as cardiovascular protection. As with other statins, common side effects may include muscle pain, liver enzyme elevation, and gastrointestinal disturbances. However, its specific safety and efficacy profile would be determined through clinical studies and regulatory evaluations. Overall, bervastatin represents a significant advancement in the management of dyslipidemia and cardiovascular risk.

bervastatin

132017-01-7: Bervastatin, with the CAS number 132017-01-7, is a synthetic compound belonging to the class of statins, which are primarily used to lower cholesterol levels in the blood. Statins function by inhibiting the enzyme HMG-CoA reductase, a key player in the cholesterol biosynthesis pathway. Bervastatin is characterized by its ability to reduce low-density lipoprotein (LDL) cholesterol and triglycerides while potentially increasing high-density lipoprotein (HDL) cholesterol. This compound exhibits a favorable pharmacokinetic profile, including good oral bioavailability and a relatively long half-life, allowing for once-daily dosing. Additionally, bervastatin may possess anti-inflammatory properties and has been studied for its potential benefits beyond lipid-lowering, such as cardiovascular protection. As with other statins, common side effects may include muscle pain, liver enzyme elevation, and gastrointestinal disturbances. However, its specific safety and efficacy profile would be determined through clinical studies and regulatory evaluations. Overall, bervastatin represents a significant advancement in the management of dyslipidemia and cardiovascular risk.

CAS 132017-01-7

bervastatin